ID   MERTK_HUMAN             Reviewed;         999 AA.
AC   Q12866; Q9HBB4;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 2.
DT   12-OCT-2022, entry version 223.
DE   RecName: Full=Tyrosine-protein kinase Mer;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Mer;
DE   AltName: Full=Receptor tyrosine kinase MerTK;
DE   Flags: Precursor;
GN   Name=MERTK; Synonyms=MER;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-118.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=8086340;
RA   Graham D.K., Dawson T.L., Mullaney D.L., Snodgrass H.R., Earp H.S.;
RT   "Cloning and mRNA expression analysis of a novel human protooncogene, c-
RT   mer.";
RL   Cell Growth Differ. 5:647-657(1994).
RN   [2]
RP   ERRATUM OF PUBMED:8086340.
RA   Graham D.K., Dawson T.L., Mullaney D.L., Snodgrass H.R., Earp H.S.;
RL   Cell Growth Differ. 5:1022-1022(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-999, VARIANTS RP38 LYS-540; CYS-661
RP   AND THR-871, AND VARIANTS SER-20; ASN-118; THR-282; HIS-293; LYS-466;
RP   SER-498; VAL-518 AND VAL-871.
RX   PubMed=11062461; DOI=10.1038/81555;
RA   Gal A., Li Y., Thompson D.A., Weir J., Orth U., Jacobson S.G.,
RA   Apfelstedt-Sylla E., Vollrath D.;
RT   "Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy
RT   gene, cause retinitis pigmentosa.";
RL   Nat. Genet. 26:270-271(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   PHOSPHORYLATION AT TYR-749; TYR-753 AND TYR-754.
RX   PubMed=8702477; DOI=10.1074/jbc.271.31.18355;
RA   Ling L., Templeton D., Kung H.J.;
RT   "Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-
RT   related receptor tyrosine kinase.";
RL   J. Biol. Chem. 271:18355-18362(1996).
RN   [6]
RP   INTERACTION WITH GAS6.
RX   PubMed=9160883; DOI=10.1038/sj.onc.1201039;
RA   Chen J., Carey K., Godowski P.J.;
RT   "Identification of Gas6 as a ligand for Mer, a neural cell adhesion
RT   molecule related receptor tyrosine kinase implicated in cellular
RT   transformation.";
RL   Oncogene 14:2033-2039(1997).
RN   [7]
RP   INTERACTION WITH VAV1.
RX   PubMed=12920122; DOI=10.1074/jbc.m305817200;
RA   Mahajan N.P., Earp H.S.;
RT   "An SH2 domain-dependent, phosphotyrosine-independent interaction between
RT   Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing
RT   guanine nucleotide-exchange factor action.";
RL   J. Biol. Chem. 278:42596-42603(2003).
RN   [8]
RP   INTERACTION WITH TNK2.
RX   PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127;
RA   Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.;
RT   "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of
RT   Ack1 in polyubiquitination of tumor suppressor Wwox.";
RL   Cancer Res. 65:10514-10523(2005).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-442.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=16737840; DOI=10.1016/j.cytogfr.2006.04.004;
RA   Hafizi S., Dahlback B.;
RT   "Signalling and functional diversity within the Axl subfamily of receptor
RT   tyrosine kinases.";
RL   Cytokine Growth Factor Rev. 17:295-304(2006).
RN   [11]
RP   FUNCTION AS CELL ENTRY FACTOR IN FILOVIRUS INFECTION.
RX   PubMed=17005688; DOI=10.1128/jvi.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T.,
RA   Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=18421305; DOI=10.1038/nri2303;
RA   Lemke G., Rothlin C.V.;
RT   "Immunobiology of the TAM receptors.";
RL   Nat. Rev. Immunol. 8:327-336(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543 AND SER-935, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   INTERACTION WITH LGALS3.
RX   PubMed=21792939; DOI=10.1002/jcp.22955;
RA   Caberoy N.B., Alvarado G., Bigcas J.L., Li W.;
RT   "Galectin-3 is a new MerTK-specific eat-me signal.";
RL   J. Cell. Physiol. 227:401-407(2012).
RN   [15]
RP   FUNCTION, INTERACTION WITH TIMD4, AND SUBCELLULAR LOCATION.
RX   PubMed=32640697; DOI=10.3390/cells9071625;
RA   Moon B., Lee J., Lee S.A., Min C., Moon H., Kim D., Yang S., Moon H.,
RA   Jeon J., Joo Y.E., Park D.;
RT   "Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis.";
RL   Cells 9:0-0(2020).
RN   [16]
RP   STRUCTURE BY NMR OF 366-483.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the FN3 domain of human proto-oncogene tyrosine-
RT   protein kinase MER precursor.";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-20; ASN-118; MET-185; THR-282; LYS-289;
RP   HIS-293; GLY-446; LEU-452; LYS-466; SER-498; VAL-518; GLU-662; SER-708;
RP   GLN-823; TRP-865 AND ILE-870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [18]
RP   VARIANTS VAL-214 AND LEU-958.
RX   PubMed=21602930; DOI=10.1371/journal.pone.0019458;
RA   Li L., Xiao X., Li S., Jia X., Wang P., Guo X., Jiao X., Zhang Q.,
RA   Hejtmancik J.F.;
RT   "Detection of variants in 15 genes in 87 unrelated Chinese patients with
RT   Leber congenital amaurosis.";
RL   PLoS ONE 6:E19458-E19458(2011).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the
CC       extracellular matrix into the cytoplasm by binding to several ligands
CC       including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological
CC       processes including cell survival, migration, differentiation, and
CC       phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the
CC       cell surface induces autophosphorylation of MERTK on its intracellular
CC       domain that provides docking sites for downstream signaling molecules.
CC       Following activation by ligand, interacts with GRB2 or PLCG2 and
CC       induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK
CC       signaling plays a role in various processes such as macrophage
CC       clearance of apoptotic cells, platelet aggregation, cytoskeleton
CC       reorganization and engulfment (PubMed:32640697). Functions in the
CC       retinal pigment epithelium (RPE) as a regulator of rod outer segments
CC       fragments phagocytosis. Also plays an important role in inhibition of
CC       Toll-like receptors (TLRs)-mediated innate immune response by
CC       activating STAT1, which selectively induces production of suppressors
CC       of cytokine signaling SOCS1 and SOCS3. {ECO:0000269|PubMed:17005688,
CC       ECO:0000269|PubMed:32640697}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Interacts (upon activation) with TNK2; stimulates TNK2
CC       autophosphorylation. Interacts (via N-terminus) with extracellular
CC       ligands LGALS3, TUB, TULP1 and GAS6 (By similarity). Interacts with
CC       VAV1 in a phosphotyrosine-independent manner. Interacts with TIMD4;
CC       this interaction enhances TIMD4-mediated efferocytosis
CC       (PubMed:32640697). {ECO:0000250, ECO:0000269|PubMed:12920122,
CC       ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:21792939,
CC       ECO:0000269|PubMed:32640697, ECO:0000269|PubMed:9160883}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32640697};
CC       Single-pass type I membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Not expressed in normal B- and T-lymphocytes but is
CC       expressed in numerous neoplastic B- and T-cell lines. Highly expressed
CC       in testis, ovary, prostate, lung, and kidney, with lower expression in
CC       spleen, small intestine, colon, and liver.
CC   -!- PTM: Autophosphorylated on Tyr-749, Tyr-753 and Tyr-754 in the
CC       activation loop allowing full activity. Autophosphorylated on Tyr-872
CC       leading to recruitment of downstream partners of the signaling cascade
CC       such as PLCG2 (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Retinitis pigmentosa 38 (RP38) [MIM:613862]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies. Retinitis
CC       pigmentosa is characterized by retinal pigment deposits visible on
CC       fundus examination and primary loss of rod photoreceptor cells followed
CC       by secondary loss of cone photoreceptors. Patients typically have night
CC       vision blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field and
CC       eventually central vision as well. {ECO:0000269|PubMed:11062461}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MERTKID41339ch2q13.html";
CC   -!- WEB RESOURCE: Name=Mutations of the MERTK gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/mertkmut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U08023; AAB60430.1; -; mRNA.
DR   EMBL; AH010001; AAG33129.1; -; Genomic_DNA.
DR   EMBL; AC093675; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104651; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2094.1; -.
DR   PIR; I38547; I38547.
DR   RefSeq; NP_006334.2; NM_006343.2.
DR   PDB; 2DBJ; NMR; -; A=373-483.
DR   PDB; 2P0C; X-ray; 2.40 A; A/B=570-864.
DR   PDB; 3BPR; X-ray; 2.80 A; A/B/C/D=570-864.
DR   PDB; 3BRB; X-ray; 1.90 A; A/B=570-864.
DR   PDB; 3TCP; X-ray; 2.69 A; A/B=570-864.
DR   PDB; 4M3Q; X-ray; 2.72 A; A/B=570-864.
DR   PDB; 4MH7; X-ray; 2.51 A; A/B=570-864.
DR   PDB; 4MHA; X-ray; 2.59 A; A/B=570-864.
DR   PDB; 5K0K; X-ray; 2.54 A; A/B=570-864.
DR   PDB; 5K0X; X-ray; 2.23 A; A/B=570-864.
DR   PDB; 5TC0; X-ray; 2.24 A; A/B=570-864.
DR   PDB; 5TD2; X-ray; 2.68 A; A/B=577-861.
DR   PDB; 5U6C; X-ray; 2.10 A; A/B=570-864.
DR   PDB; 6MEP; X-ray; 2.89 A; A/B=570-864.
DR   PDB; 7AAX; X-ray; 1.76 A; A=571-864.
DR   PDB; 7AAY; X-ray; 1.87 A; A=571-864.
DR   PDB; 7AAZ; X-ray; 1.85 A; A=570-864.
DR   PDB; 7AB0; X-ray; 1.74 A; A=571-864.
DR   PDB; 7AB1; X-ray; 1.93 A; A=571-864.
DR   PDB; 7AB2; X-ray; 1.78 A; A=571-864.
DR   PDB; 7AVX; X-ray; 2.44 A; A/B=570-864.
DR   PDB; 7AVY; X-ray; 2.31 A; A=570-864.
DR   PDB; 7AVZ; X-ray; 2.04 A; A=571-864.
DR   PDB; 7AW0; X-ray; 1.89 A; A=571-864.
DR   PDB; 7AW1; X-ray; 1.98 A; A=571-864.
DR   PDB; 7AW2; X-ray; 2.10 A; A=571-864.
DR   PDB; 7AW3; X-ray; 1.99 A; A=571-864.
DR   PDB; 7AW4; X-ray; 1.98 A; A/B=570-864.
DR   PDB; 7CQE; X-ray; 2.69 A; A/C=571-864.
DR   PDB; 7DXL; X-ray; 3.15 A; A/B=570-864.
DR   PDB; 7M5Z; X-ray; 3.06 A; A/B=570-864.
DR   PDB; 7OAM; X-ray; 2.65 A; A/B=571-864.
DR   PDB; 7OLS; X-ray; 1.89 A; A=571-864.
DR   PDB; 7OLV; X-ray; 2.13 A; A=571-864.
DR   PDB; 7OLX; X-ray; 1.98 A; A=571-864.
DR   PDBsum; 2DBJ; -.
DR   PDBsum; 2P0C; -.
DR   PDBsum; 3BPR; -.
DR   PDBsum; 3BRB; -.
DR   PDBsum; 3TCP; -.
DR   PDBsum; 4M3Q; -.
DR   PDBsum; 4MH7; -.
DR   PDBsum; 4MHA; -.
DR   PDBsum; 5K0K; -.
DR   PDBsum; 5K0X; -.
DR   PDBsum; 5TC0; -.
DR   PDBsum; 5TD2; -.
DR   PDBsum; 5U6C; -.
DR   PDBsum; 6MEP; -.
DR   PDBsum; 7AAX; -.
DR   PDBsum; 7AAY; -.
DR   PDBsum; 7AAZ; -.
DR   PDBsum; 7AB0; -.
DR   PDBsum; 7AB1; -.
DR   PDBsum; 7AB2; -.
DR   PDBsum; 7AVX; -.
DR   PDBsum; 7AVY; -.
DR   PDBsum; 7AVZ; -.
DR   PDBsum; 7AW0; -.
DR   PDBsum; 7AW1; -.
DR   PDBsum; 7AW2; -.
DR   PDBsum; 7AW3; -.
DR   PDBsum; 7AW4; -.
DR   PDBsum; 7CQE; -.
DR   PDBsum; 7DXL; -.
DR   PDBsum; 7M5Z; -.
DR   PDBsum; 7OAM; -.
DR   PDBsum; 7OLS; -.
DR   PDBsum; 7OLV; -.
DR   PDBsum; 7OLX; -.
DR   AlphaFoldDB; Q12866; -.
DR   SMR; Q12866; -.
DR   BioGRID; 115724; 14.
DR   IntAct; Q12866; 109.
DR   MINT; Q12866; -.
DR   STRING; 9606.ENSP00000295408; -.
DR   BindingDB; Q12866; -.
DR   ChEMBL; CHEMBL5331; -.
DR   DrugBank; DB08325; 2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q12866; -.
DR   GuidetoPHARMACOLOGY; 1837; -.
DR   CarbonylDB; Q12866; -.
DR   GlyConnect; 1870; 15 N-Linked glycans (7 sites).
DR   GlyGen; Q12866; 18 sites, 1 Asn glycan (1 site), 15 N-linked glycans (7 sites), 2 Thr glycans (2 sites).
DR   iPTMnet; Q12866; -.
DR   PhosphoSitePlus; Q12866; -.
DR   BioMuta; MERTK; -.
DR   DMDM; 160332297; -.
DR   EPD; Q12866; -.
DR   jPOST; Q12866; -.
DR   MassIVE; Q12866; -.
DR   MaxQB; Q12866; -.
DR   PaxDb; Q12866; -.
DR   PeptideAtlas; Q12866; -.
DR   PRIDE; Q12866; -.
DR   ProteomicsDB; 58992; -.
DR   Antibodypedia; 33255; 873 antibodies from 42 providers.
DR   DNASU; 10461; -.
DR   Ensembl; ENST00000295408.9; ENSP00000295408.4; ENSG00000153208.18.
DR   Ensembl; ENST00000421804.6; ENSP00000389152.2; ENSG00000153208.18.
DR   GeneID; 10461; -.
DR   KEGG; hsa:10461; -.
DR   MANE-Select; ENST00000295408.9; ENSP00000295408.4; NM_006343.3; NP_006334.2.
DR   UCSC; uc002thk.2; human.
DR   CTD; 10461; -.
DR   DisGeNET; 10461; -.
DR   GeneCards; MERTK; -.
DR   GeneReviews; MERTK; -.
DR   HGNC; HGNC:7027; MERTK.
DR   HPA; ENSG00000153208; Low tissue specificity.
DR   MalaCards; MERTK; -.
DR   MIM; 604705; gene.
DR   MIM; 613862; phenotype.
DR   neXtProt; NX_Q12866; -.
DR   OpenTargets; ENSG00000153208; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA30759; -.
DR   VEuPathDB; HostDB:ENSG00000153208; -.
DR   eggNOG; ENOG502QQQ3; Eukaryota.
DR   GeneTree; ENSGT00940000155669; -.
DR   InParanoid; Q12866; -.
DR   OMA; LVIKWKP; -.
DR   OrthoDB; 263089at2759; -.
DR   PhylomeDB; Q12866; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q12866; -.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   SignaLink; Q12866; -.
DR   SIGNOR; Q12866; -.
DR   BioGRID-ORCS; 10461; 13 hits in 1108 CRISPR screens.
DR   ChiTaRS; MERTK; human.
DR   EvolutionaryTrace; Q12866; -.
DR   GeneWiki; MERTK; -.
DR   GenomeRNAi; 10461; -.
DR   Pharos; Q12866; Tchem.
DR   PRO; PR:Q12866; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q12866; protein.
DR   Bgee; ENSG00000153208; Expressed in right adrenal gland cortex and 158 other tissues.
DR   ExpressionAtlas; Q12866; baseline and differential.
DR   Genevisible; Q12866; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0001750; C:photoreceptor outer segment; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0001779; P:natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:0001818; P:negative regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:2000107; P:negative regulation of leukocyte apoptotic process; IMP:CACAO.
DR   GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IMP:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0032940; P:secretion by cell; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Disease variant; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Retinitis pigmentosa; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..999
FT                   /note="Tyrosine-protein kinase Mer"
FT                   /id="PRO_0000024443"
FT   TOPO_DOM        21..505
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        506..526
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        527..999
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          81..186
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          197..273
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          286..381
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          386..484
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          587..858
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        723
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         593..601
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         615
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         543
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         749
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8702477"
FT   MOD_RES         753
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8702477"
FT   MOD_RES         754
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8702477"
FT   MOD_RES         872
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q60805"
FT   MOD_RES         935
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   CARBOHYD        114
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        170
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        207
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        215
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        234
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        294
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        316
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        329
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        336
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        354
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        389
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        395
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        442
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        454
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        115..175
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        218..262
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VARIANT         20
FT                   /note="R -> S (in dbSNP:rs35898499)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021039"
FT   VARIANT         118
FT                   /note="S -> N (in dbSNP:rs13027171)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8086340"
FT                   /id="VAR_021040"
FT   VARIANT         185
FT                   /note="V -> M (in dbSNP:rs56205303)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041741"
FT   VARIANT         214
FT                   /note="F -> V (found in a patient with Leber congenital
FT                   amaurosis; dbSNP:rs1475870132)"
FT                   /evidence="ECO:0000269|PubMed:21602930"
FT                   /id="VAR_067194"
FT   VARIANT         282
FT                   /note="A -> T (in dbSNP:rs7588635)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021041"
FT   VARIANT         289
FT                   /note="E -> K (in dbSNP:rs766215580)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041742"
FT   VARIANT         293
FT                   /note="R -> H (in dbSNP:rs34072093)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021042"
FT   VARIANT         329
FT                   /note="N -> S (in dbSNP:rs34943572)"
FT                   /id="VAR_051698"
FT   VARIANT         446
FT                   /note="A -> G (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041743"
FT   VARIANT         452
FT                   /note="V -> L (in dbSNP:rs34010621)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041744"
FT   VARIANT         466
FT                   /note="R -> K (in dbSNP:rs7604639)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021043"
FT   VARIANT         498
FT                   /note="N -> S (in dbSNP:rs35858762)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021044"
FT   VARIANT         518
FT                   /note="I -> V (in dbSNP:rs2230515)"
FT                   /evidence="ECO:0000269|PubMed:11062461,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021045"
FT   VARIANT         540
FT                   /note="E -> K (in RP38; dbSNP:rs113485015)"
FT                   /evidence="ECO:0000269|PubMed:11062461"
FT                   /id="VAR_021046"
FT   VARIANT         661
FT                   /note="S -> C (in RP38)"
FT                   /evidence="ECO:0000269|PubMed:11062461"
FT                   /id="VAR_021047"
FT   VARIANT         662
FT                   /note="Q -> E (in dbSNP:rs56209758)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041745"
FT   VARIANT         708
FT                   /note="A -> S (in a head & Neck squamous cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041746"
FT   VARIANT         823
FT                   /note="E -> Q (in dbSNP:rs55924349)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041747"
FT   VARIANT         865
FT                   /note="R -> W (in dbSNP:rs2230516)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_020285"
FT   VARIANT         870
FT                   /note="V -> I (in dbSNP:rs2230517)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_029237"
FT   VARIANT         871
FT                   /note="I -> T (in RP38; dbSNP:rs377341255)"
FT                   /evidence="ECO:0000269|PubMed:11062461"
FT                   /id="VAR_021048"
FT   VARIANT         871
FT                   /note="I -> V"
FT                   /evidence="ECO:0000269|PubMed:11062461"
FT                   /id="VAR_021049"
FT   VARIANT         958
FT                   /note="P -> L (found in a patient with Leber congenital
FT                   amaurosis; dbSNP:rs201460398)"
FT                   /evidence="ECO:0000269|PubMed:21602930"
FT                   /id="VAR_067195"
FT   CONFLICT        140
FT                   /note="A -> G (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        143
FT                   /note="A -> R (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="S -> G (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        274
FT                   /note="K -> Q (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        328
FT                   /note="S -> G (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        628
FT                   /note="Q -> H (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        794
FT                   /note="A -> R (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        888
FT                   /note="S -> P (in Ref. 1; AAB60430)"
FT                   /evidence="ECO:0000305"
FT   STRAND          388..394
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          396..406
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          417..428
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          431..441
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          446..449
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          453..459
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          461..467
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   STRAND          476..479
FT                   /evidence="ECO:0007829|PDB:2DBJ"
FT   HELIX           571..580
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           584..586
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          587..595
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          600..607
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          613..620
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          624..626
FT                   /evidence="ECO:0007829|PDB:7AVX"
FT   HELIX           628..643
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          654..659
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          661..663
FT                   /evidence="ECO:0007829|PDB:7OLS"
FT   STRAND          665..672
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           679..685
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          688..692
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           697..716
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           726..728
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          729..731
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   TURN            733..735
FT                   /evidence="ECO:0007829|PDB:7M5Z"
FT   STRAND          737..739
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           758..761
FT                   /evidence="ECO:0007829|PDB:7AAZ"
FT   HELIX           764..766
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           769..773
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           779..794
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          800..804
FT                   /evidence="ECO:0007829|PDB:7M5Z"
FT   HELIX           806..808
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           809..814
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   STRAND          822..824
FT                   /evidence="ECO:0007829|PDB:7AVX"
FT   HELIX           827..835
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           841..843
FT                   /evidence="ECO:0007829|PDB:7AB0"
FT   HELIX           847..860
FT                   /evidence="ECO:0007829|PDB:7AB0"
SQ   SEQUENCE   999 AA;  110249 MW;  05BC339F05DFD355 CRC64;
     MGPAPLPLLL GLFLPALWRR AITEAREEAK PYPLFPGPFP GSLQTDHTPL LSLPHASGYQ
     PALMFSPTQP GRPHTGNVAI PQVTSVESKP LPPLAFKHTV GHIILSEHKG VKFNCSISVP
     NIYQDTTISW WKDGKELLGA HHAITQFYPD DEVTAIIASF SITSVQRSDN GSYICKMKIN
     NEEIVSDPIY IEVQGLPHFT KQPESMNVTR NTAFNLTCQA VGPPEPVNIF WVQNSSRVNE
     QPEKSPSVLT VPGLTEMAVF SCEAHNDKGL TVSKGVQINI KAIPSPPTEV SIRNSTAHSI
     LISWVPGFDG YSPFRNCSIQ VKEADPLSNG SVMIFNTSAL PHLYQIKQLQ ALANYSIGVS
     CMNEIGWSAV SPWILASTTE GAPSVAPLNV TVFLNESSDN VDIRWMKPPT KQQDGELVGY
     RISHVWQSAG ISKELLEEVG QNGSRARISV QVHNATCTVR IAAVTRGGVG PFSDPVKIFI
     PAHGWVDYAP SSTPAPGNAD PVLIIFGCFC GFILIGLILY ISLAIRKRVQ ETKFGNAFTE
     EDSELVVNYI AKKSFCRRAI ELTLHSLGVS EELQNKLEDV VIDRNLLILG KILGEGEFGS
     VMEGNLKQED GTSLKVAVKT MKLDNSSQRE IEEFLSEAAC MKDFSHPNVI RLLGVCIEMS
     SQGIPKPMVI LPFMKYGDLH TYLLYSRLET GPKHIPLQTL LKFMVDIALG MEYLSNRNFL
     HRDLAARNCM LRDDMTVCVA DFGLSKKIYS GDYYRQGRIA KMPVKWIAIE SLADRVYTSK
     SDVWAFGVTM WEIATRGMTP YPGVQNHEMY DYLLHGHRLK QPEDCLDELY EIMYSCWRTD
     PLDRPTFSVL RLQLEKLLES LPDVRNQADV IYVNTQLLES SEGLAQGSTL APLDLNIDPD
     SIIASCTPRA AISVVTAEVH DSKPHEGRYI LNGGSEEWED LTSAPSAAVT AEKNSVLPGE
     RLVRNGVSWS HSSMLPLGSS LPDELLFADD SSEGSEVLM
//
